Sci pharmatech stanozolol

This acquisition lays the groundwork for the creation of an integrated global enterprise with unique advantages for applying genomics to medicine. It broadens and enhances WuXi’s existing genomic laboratory services for biopharmaceutical research and clinical development, as well as NextCODE’s unique capabilities in genome analysis. It provides global commercial customers of both entities with comprehensive genomic and bioinformatic capabilities, from CLIA-certified whole genome and whole exome sequencing to the analysis and interpretation of that sequencing data necessary to provide effective diagnosis and treatment.

This facility further expands WuXi’s already extensive biologics manufacturing capabilities. In August 2012, WuXi completed state-of-the-art biologics clinical drug substance and drug product manufacturing facilities in Wuxi city, the first in China that met cGMP standards of the United States, the European Union and China. Since then, the facilities have ramped up quickly to produce clinical supplies for the US, EU, China and other markets. In March 2014, the drug substance facility received the honorable mention “facility-of-the-year” award by International Society For Professional Engineering (ISPE), a first for China.

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, visit http://.

Sci pharmatech stanozolol

sci pharmatech stanozolol

About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, visit http://.

Media:



http://buy-steroids.org